Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Seevix Material Sciences is an Israeli private biotechnology and biomaterials company developing recombinant spider-silk-inspired biopolymers for healthcare and industrial applications. Its core platform, SVX, is a patented biomimetic material produced through recombinant DNA technology and controlled self-assembly to generate spider-silk-like nanofibers without animal sourcing. In life science applications, the company markets products such as SpheroSeev and HydroSeev for 3D cell culture, spheroid formation, and tissue-modeling workflows, and it is also developing medical-material applications including sutures, implants, bio-inks, and tissue-engineering scaffolds. Beyond healthcare, Seevix positions SVX for composites and cosmetics, emphasizing sustainability, biocompatibility, and improved mechanical performance. The company appears to be an active, venture-backed spinout associated with Yissum and the Hebrew University ecosystem in Jerusalem.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Seevix Material Sciences.